Project Details
Abstract
The objective of this research is to investigate the effective treatment of patients with
colorectal cancer. Previously we have successfully uncovered several differentially expressed
proteins in colorectal carcinoma by using gel-assisted digestion and Itraq labeling or
label-free mass spectrophotometry. The results have revealed that 23 selected differentially
expressed proteins, including stomatin-like protein 2 (SLP-2), phospholipid scramblase 1
(PLSCR 1) and transport protein Sec61 subunit beta (SEC61β), may play an important role in
colorectal cancer carcinogenesis and can serve as promising diagnostic or therapeutic targets
for colorectal cancer. Preliminary results have shown the therapy by targeting the activity of
PLSCR1 is clearly effective against colorectal cancer both in colorectal cell line (HT29 cell
line) and in a mouse model. This proposal hypothesize that the apparent dependency of
colorectal cancer on one or a few specific proteins for maintenance of the malignant
phenotype. To prove this hypothesis, we will evaluate the therapy efficacy of agents against
the activity of specific proteins in colorectal cancer and investigate the influence of
differentially expressed proteins on the signal transduction. The strategy combines the use of
RNA interference, antibody against specific protein, cell proliferation assay, soft agar colony
assay, migration assay and invasion assay to identify the specific proteins that are critical for
maintenance of the malignant phenotype of colorectal cancer. Once the dependency of the
specific proteins for maintenance of the malignant phenotype have been identified, we will
apply this mode of therapeutic approach to mouse models. The results enabled us to uncover
that survival of mice with transplanted colorectal cancer can be significantly improved after a
treatment by administering an antibody or siRNA against one or more of the specific proteins.
Furthermore, we will also investigate the signal transduction pathway of the specific proteins
in colorectal cancer carcinogenesis by treating HT29 cell line with siRNA against the specific
protein. The results of this project will help us understand the dependency of specific proteins
for maintenance of the malignant phenotype and develop more effective and specific forms of
colorectal cancer prevention and therapy.
Project IDs
Project ID:PC10308-1711
External Project ID:MOST103-2320-B182-019
External Project ID:MOST103-2320-B182-019
| Status | Finished |
|---|---|
| Effective start/end date | 01/08/14 → 31/07/15 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.